SCHEMBL31367415

SCHEMBL31367415

Cc1ccccc1-c1cc(-c2ccccc2)cn2cc(-c3ccccc3)nc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
NPC1 O15118 6/20 0.56
RAB9A P51151 6/20 0.56
KDM4E B2RXH2 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
TP53 P04637 3/20 0.56
HSD17B10 Q99714 3/20 0.56
HPGD P15428 2/20 0.56
TSHR P16473 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
ALDH1A3 P47895 8/20 0.54
ALDH1A2 O94788 4/20 0.54
ADORA1 P30542 3/20 0.49
ADORA2A P29274 2/20 0.49
SLC2A1 P11166 1/20 0.48
NFKB1 P19838 3/20 0.44
NFKB2 Q00653 3/20 0.44
RELA Q04206 3/20 0.44
GAA P10253 1/20 0.44
PKM P14618 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31367429 0.89 ALDH1A3 (0.54) ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL31367603 0.89 ALDH1A3 (0.57) ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL31367607 0.85 ALDH1A3 (0.63) ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL31367492 0.83 ALDH1A3 (0.54) ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL31367540 0.83 ALDH1A3 (0.54) ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL31367614 0.83 ALDH1A3 (0.54) ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL31367458 0.83 ALDH1A3 (0.62) ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL31367573 0.83 ALDH1A3 (0.54) ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL31367421 0.83 ALDH1A3 (0.54) ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL31367386 0.83 ALDH1A3 (0.62) ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP claimed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US claimed
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP disclosed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A ALDH2, ALDH3A1, ALDH1A1 ALDH1A1 3/4885NPC1 1136/4885RAB9A 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.